Terns Pharmaceuticals (NASDAQ:TERN) Now Covered by Analysts at Leerink Partners

Equities researchers at Leerink Partners began coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN) in a report released on Monday. The firm set an “outperform” rating and a $58.00 price target on the stock. Leerink Partners’ price target indicates a potential upside of 53.72% from the company’s current price.

Several other equities research analysts have also recently issued reports on the stock. BMO Capital Markets raised their target price on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. JMP Securities set a $35.00 price target on Terns Pharmaceuticals in a research note on Wednesday, November 26th. Citizens Jmp lifted their price objective on Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a report on Thursday, December 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen downgraded Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Terns Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $55.80.

Terns Pharmaceuticals Stock Performance

NASDAQ TERN opened at $37.73 on Monday. Terns Pharmaceuticals has a one year low of $1.87 and a one year high of $48.26. The stock has a 50-day moving average of $37.67 and a 200 day moving average of $20.23. The company has a market capitalization of $3.40 billion, a price-to-earnings ratio of -36.63 and a beta of -0.28.

Terns Pharmaceuticals (NASDAQ:TERN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. On average, equities analysts predict that Terns Pharmaceuticals will post -1.19 earnings per share for the current fiscal year.

Insider Transactions at Terns Pharmaceuticals

In related news, CEO Amy L. Burroughs sold 68,749 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $37.07, for a total transaction of $2,548,525.43. Following the completion of the transaction, the chief executive officer directly owned 288,976 shares in the company, valued at approximately $10,712,340.32. The trade was a 19.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the sale, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. The trade was a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 141,243 shares of company stock valued at $5,311,090. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TERN. GAMMA Investing LLC raised its position in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after purchasing an additional 770 shares during the period. Engineers Gate Manager LP purchased a new stake in Terns Pharmaceuticals in the 2nd quarter worth $41,000. iA Global Asset Management Inc. bought a new stake in Terns Pharmaceuticals during the fourth quarter valued at about $43,000. Canada Pension Plan Investment Board purchased a new position in shares of Terns Pharmaceuticals in the second quarter valued at about $46,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Terns Pharmaceuticals in the first quarter worth about $51,000. 98.26% of the stock is owned by hedge funds and other institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.